Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | — | PO / MO |
The patient supposed to took Vivotif last night, forgot and took it next morning; Case reference number US-BN-2025-000158 is a spontaneous case initially received from a nurse via Communications (reference number: USBAV25-0181) on 23-Jan-2025 and concerns a female patient with unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient received a dose of Vivotif vaccine (batch number: unknown) at unknown dose or site of administration, for typhoid immunization. On 23-Jan-2025, unknown of time after previous dose of Vivotif, as reported the patient forgot to take vaccine last night on 22-Jan-2025, so in the morning, the patient took Vivotif vaccine (batch number: unknown) orally, at unknown dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age forgot to take vaccine last night (on 22-Jan-2025), so in the morning, the patient took Vivotif vaccine, orally, at unknown dose which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age forgot to take vaccine last night (on 22-Jan-2025), so in the morning, the patient took Vivotif vaccine, orally, at unknown dose which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE